These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28986430)

  • 1. How entry inhibitors synergize to fight HIV.
    Melikyan GB
    J Biol Chem; 2017 Oct; 292(40):16511-16512. PubMed ID: 28986430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors.
    Ahn KW; Root MJ
    J Biol Chem; 2017 Oct; 292(40):16498-16510. PubMed ID: 28696261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
    Ray N; Harrison JE; Blackburn LA; Martin JN; Deeks SG; Doms RW
    J Virol; 2007 Apr; 81(7):3240-50. PubMed ID: 17251281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions.
    Giroud C; Marin M; Hammonds J; Spearman P; Melikyan GB
    J Virol; 2015 Sep; 89(18):9368-82. PubMed ID: 26136569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates.
    Chabot DJ; Zhang PF; Quinnan GV; Broder CC
    J Virol; 1999 Aug; 73(8):6598-609. PubMed ID: 10400757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex.
    Welman M; Lemay G; Cohen EA
    Virus Res; 2007 Mar; 124(1-2):103-12. PubMed ID: 17129629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
    Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
    Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Field-Based Affinity Optimization of a Novel Azabicyclohexane Scaffold HIV-1 Entry Inhibitor.
    Meuser ME; Rashad AA; Ozorowski G; Dick A; Ward AB; Cocklin S
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31013646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of HIV-1 entry: multiple keys to close the door.
    Hertje M; Zhou M; Dietrich U
    ChemMedChem; 2010 Nov; 5(11):1825-35. PubMed ID: 20845361
    [No Abstract]   [Full Text] [Related]  

  • 10. "Fusion and binding inhibition" key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches.
    Malik T; Chauhan G; Rath G; Murthy RS; Goyal AK
    Drug Deliv; 2017 Nov; 24(1):608-621. PubMed ID: 28240046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.
    Marin M; Du Y; Giroud C; Kim JH; Qui M; Fu H; Melikyan GB
    Assay Drug Dev Technol; 2015 Apr; 13(3):155-66. PubMed ID: 25871547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P2X1 Selective Antagonists Block HIV-1 Infection through Inhibition of Envelope Conformation-Dependent Fusion.
    Soare AY; Malik HS; Durham ND; Freeman TL; Alvarez R; Patel F; Satija N; Upadhyay C; Hioe CE; Chen BK; Swartz TH
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31852781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entry inhibitors and their use in the treatment of HIV-1 infection.
    Haqqani AA; Tilton JC
    Antiviral Res; 2013 May; 98(2):158-70. PubMed ID: 23541872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
    Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of HIV-1 by fusion inhibitors.
    Eggink D; Berkhout B; Sanders RW
    Curr Pharm Des; 2010; 16(33):3716-28. PubMed ID: 21128887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Polar Region of the HIV-1 Envelope Protein Determines Viral Fusion and Infectivity by Stabilizing the gp120-gp41 Association.
    Lu W; Chen S; Yu J; Behrens R; Wiggins J; Sherer N; Liu SL; Xiong Y; Xiang SH; Wu L
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanism of HIV-1 Entry.
    Chen B
    Trends Microbiol; 2019 Oct; 27(10):878-891. PubMed ID: 31262533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure.
    Nieto-Garai JA; Glass B; Bunn C; Giese M; Jennings G; Brankatschk B; Agarwal S; Börner K; Contreras FX; Knölker HJ; Zankl C; Simons K; Schroeder C; Lorizate M; Kräusslich HG
    Front Immunol; 2018; 9():1983. PubMed ID: 30233582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.